Search results

Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.

Result type

Technology appraisal guidance

Published

1 November 2017

Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

Result type

Technology appraisal guidance

Published

22 July 2015

Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

24 July 2013

Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

Result type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.

Result type

Technology appraisal guidance

Published

26 February 2014

  Status ...

Result type

Technology appraisal guidance

Status

Topic selection

Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

Result type

Technology appraisal guidance

Published

25 March 2014

  Status ...

Result type

Technology appraisal guidance

Status

Topic selection

In development [GID-TA11193] Expected publication date: 04 December 2024

Result type

Technology appraisal guidance

Status

In development

This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

Result type

NICE guideline

Published

23 January 2018

Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

3 February 2021

Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

29 June 2022

Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.

Result type

Technology appraisal guidance

Published

29 June 2022

Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

Result type

Technology appraisal guidance

Published

31 August 2022

Evidence-based recommendations on faricimab (Vabysmo) for treating visual impairment caused by macular oedema after retinal vein occlusion in adults.

Result type

Technology appraisal guidance

Published

11 September 2024